CorMedix, Inc.

Contributing Author

Recent Articles by CorMedix, Inc.

Sep-01	CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference CRMD GlobeNewswire
Aug-13	Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update CRMD +14.65% GlobeNewswire
Jul-29	CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 CRMD GlobeNewswire
Jun-08	U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation CRMD GlobeNewswire
May-15	Cormedix Therapeutics to Participate in two Upcoming Investor Conferences CRMD GlobeNewswire
May-14	Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update CRMD +5.73% GlobeNewswire
May-05	CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 CRMD GlobeNewswire
Apr-27	CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients CRMD +5.39% GlobeNewswire
Apr-07	CorMedix to Participate in Needham Virtual Healthcare Conference CRMD GlobeNewswire
Mar-05	CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update CRMD -11.52% GlobeNewswire
Mar-02	CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 CRMD GlobeNewswire
Feb-12	CorMedix to Participate in Upcoming Investor Conferences CRMD GlobeNewswire
Feb-02	CorMedix Therapeutics Announces Share Repurchase Program CRMD +5.28% GlobeNewswire
Jan-29	CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 CRMD GlobeNewswire
Jan-09	CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference CRMD GlobeNewswire
Jan-08	CorMedix Therapeutics Announces Leadership and Board Updates CRMD -32.77% GlobeNewswire
Jan-08	CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates CRMD -32.77% GlobeNewswire
Dec-18	CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath CRMD GlobeNewswire
Nov-12	CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance CRMD GlobeNewswire
Oct-31	CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 CRMD GlobeNewswire
Oct-23	CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath CRMD GlobeNewswire
Oct-20	CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance CRMD +19.45% GlobeNewswire
Sep-29	CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO CRMD GlobeNewswire
Sep-08	CorMedix Announces Strategic Minority Investment in Talphera CRMD GlobeNewswire
Sep-02	CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team CRMD GlobeNewswire
Aug-28	CorMedix to Participate in Upcoming Investor Conferences CRMD GlobeNewswire
Aug-07	Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update CRMD -9.54% GlobeNewswire
Aug-07	CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings CRMD -9.54% GlobeNewswire
Jun-27	CorMedix Inc. Announces Pricing of Public Offering of Common Stock CRMD -16.44% GlobeNewswire
Jun-26	CorMedix Inc. Announces Proposed Public Offering of Common Stock CRMD GlobeNewswire
Jun-23	CorMedix inc. Announces Customer Implementation CRMD +21.68% GlobeNewswire
May-30	CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference CRMD GlobeNewswire
May-15	CorMedix Inc. to Participate in the RBC Global Healthcare Conference CRMD GlobeNewswire
May-06	CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update CRMD +23.59% GlobeNewswire

CorMedix, Inc.

Recent Articles by CorMedix, Inc.

Upgrade your Finviz experience